CanniMed News Banner

 News

CanniMed Therapeutics Inc. Commences Cannabis Oils Facility Expansion with Support of the Saskatchewan Provincial Government

April 19, 2017

Saskatoon, Saskatchewan April 19, 2017 — CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed” or the “Company”) announced today that its directors have approved the commencement of a capital project to increase its current cannabinoid oils processing capacity by constructing a new facility on the Company’s Saskatchewan campus. The planned Good Manufacturing...
View More

CanniMed Therapeutics Inc. Receives Two Export Permits from Health Canada and Initial Purchase Orders for Distribution to Australia and the Cayman Islands

March 22, 2017

Saskatoon, Saskatchewan March 22, 2017: CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) today announced the receipt, through its wholly-owned subsidiary Prairie Plant Systems Inc., of the Company’s first two Health Canada issued export permits for medical cannabis oils. In addition, the Company has received initial purchase orders for...
View More

CanniMed Therapeutics Inc. Corrects Previously Released Q1 Average Selling Prices

March 17, 2017

Saskatoon, Saskatchewan March 17, 2017 — CanniMed Therapeutics Inc. (TSX: CMED) (“CMED” or the “Company”), provides a correction on the Company’s earnings release dated March 16, 2017, that, for the three months ended January 31, 2017, the average selling price for concentrated medical marijuana oils was $2.27 per ml and...
View More

CanniMed Therapeutics Inc. Reports Financial Results for Q1 2017

March 17, 2017

Saskatoon, Saskatchewan March 16, 2017: CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) today released its financial results for its first quarter ended January 31, 2017. “Our medical cannabis sales increased dramatically during the quarter, with increasing contribution from oils,” said Brent Zettl, President and CEO of the Company....
View More

CanniMed Therapeutics Inc. and PharmaChoice Enter into Canada’s First Exclusive Pharmacy Distribution Agreement for Medical Cannabis

March 02, 2017

SASKATOON, Saskatchewan March 2, 2017: CanniMed Therapeutics Inc. (TSX: CMED) (“CanniMed”) and PharmaChoice today signed a letter of intent to collaborate on pharmacist education and the distribution, sale and marketing of medical cannabis products. This industry-leading collaboration will see CanniMed responsible for producing and delivering accredited pharmacy education programs to...
View More

Independent Laboratory Analysis Confirms CanniMed Medical Cannabis Products Free from Pesticides, Fungicides, and Plant Growth Regulators

February 22, 2017

Saskatoon, Saskatchewan [February 22, 2017] — CanniMed Therapeutics Inc. (TSX:CMED) ) proactively commissioned an independent laboratory analysis of the Company’s herbal cannabis products to test for 56 known pesticides, fungicides and PGRs (plant growth regulators). Each analyzed lot returned a clean Certificate of Analysis with “not detected” levels for each...
View More

CTT Pharmaceutical Holdings and CanniMed Therapeutics Inc. Complete Exclusive Canadian Licensing Agreement for Cannabis Orally Dissolvable Thin Film (ODF) Wafer

February 17, 2017

SASKATOON, Saskatchewan and STONEY CREEK, Ontario [February 17, 2017]: Today, CanniMed Therapeutics Inc. (TSX: CMED) and CTT Pharmaceutical Holdings Inc. (OTCQB:CTTH) have entered into a definitive contractual relationship for the licensing of CTT’s Orally Dissolvable Thin Film (ODF) Wafer technology. This industry-first collaboration includes the licensing of six patents related...
View More

Trial Underway to Provide Scientific Validity of the Analgesic Efficacy and Safety of Medical Cannabis in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of Multiple Sclerosis (MS)-Induced Neuropathic Pain

February 14, 2017

Saskatchewan and Manitoba [February 14, 2017]: As one of the major symptoms experienced by patients with Multiple Sclerosis (MS), neuropathic pain can be extremely debilitating. A leading neuro-immunology team lead by Dr. Michael Namaka at the University of Manitoba in Winnipeg, Manitoba, is looking to determine the analgesic efficacy of...
View More

CANNIMED THERAPEUTICS INC. PROVIDES UPDATE ON PATIENT GROWTH RATES, SALES VOLUME AND PRODUCT SUPPLY

February 03, 2017

CANNIMED THERAPEUTICS INC. PROVIDES UPDATE ON PATIENT GROWTH RATES, SALES VOLUME AND PRODUCT SUPPLY NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Saskatoon, Saskatchewan [February 3, 2017] — CanniMed Therapeutics Inc. (TSX: CMED) (“CMED” or the “Company”), a leading plant biopharmaceutical company specializing in...
View More

University of Saskatchewan launches study of cannabis treatment for childhood epilepsy

February 01, 2017

SASKATOON, Feb 1, 2017 - The Pediatrics Department at the University of Saskatchewan (U of S) is launching a study examining the use of Cannabidiol (CBD) to treat children with medically intractable epilepsy and associated cognitive decline, after recently obtaining Health Canada approval to proceed. The main goal of the...
View More

CanniMed Therapeutics Inc. Closes Over-Allotment

January 30, 2017

CanniMed Therapeutics Inc. Closes Over-Allotment NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Saskatoon, Saskatchewan [January 30, 2017] — CanniMed Therapeutics Inc. (TSX:CMED) (“CMED” or the “Company”), a leading plant biopharmaceutical company specializing in the production of pharmaceutical-grade cannabis, announced today that the underwriters...
View More

CANNIMED COMPLETES INITIAL PUBLIC OFFERING

December 29, 2016

CANNIMED COMPLETES INITIAL PUBLIC OFFERING NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Saskatoon, Saskatchewan [December 29, 2016] — CanniMed Therapeutics Inc. (“CMED” or the “Company”), a leading plant biopharmaceutical company specializing in the production of pharmaceutical-grade cannabis, announced today that it has successfully...
View More

CANNIMED FILES FINAL PROSPECTUS AND ANNOUNCES PRICING FOR INITIAL PUBLIC OFFERING

December 22, 2016

CANNIMED FILES FINAL PROSPECTUS AND ANNOUNCES PRICING FOR INITIAL PUBLIC OFFERING NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Saskatoon, Saskatchewan [December 21, 2016] - CanniMed Therapeutics Inc. (“CMED” or the “Company”), a leading plant biopharmaceutical company specializing in the production of pharmaceutical-grade cannabis,...
View More

CANNIMED THERAPEUTICS INC. ANNOUNCES FILING OF AMENDED AND RESTATED PRELIMINARY PROSPECTUS

December 07, 2016

CANNIMED THERAPEUTICS INC. ANNOUNCES FILING OF AMENDED AND RESTATED PRELIMINARY PROSPECTUS NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Saskatoon, Saskatchewan [December 6] - CanniMed Therapeutics Inc. (“CMED” or the “Company”), a leading plant biopharmaceutical company specializing in the production of pharmaceutical-grade cannabis, announced...
View More

CanniMed Ltd. Partners with Canadian Cancer Survivor Network for Medical Cannabis Education

November 29, 2016

SASKATOON, Nov 29, 2016 - Medical cannabis is increasingly becoming an option considered by patients to help manage symptoms related to current or past cancer treatment. But when patients weigh the pros and cons of including this therapeutic option, a multitude of questions abound. What are the rules and regulations...
View More

CANNIMED THERAPEUTICS INC. ANNOUNCES FILING OF PRELIMINARY PROSPECTUS

November 28, 2016

CANNIMED THERAPEUTICS INC. ANNOUNCES FILING OF PRELIMINARY PROSPECTUS NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Saskatoon, Saskatchewan [November 28] - CanniMed Therapeutics Inc. (“CMED” or the “Company”), a leading plant biopharmaceutical company specializing in the production of pharmaceutical-grade cannabis, announced today that it...
View More

CanniMed Ltd. to Appoint Creso Pharma Ltd. as Preferred Distributor of Medical Cannabis Products within the European Union

November 17, 2016

SASKATOON, Nov. 17, 2016: CanniMed Ltd. has entered into a letter of intent with Creso Pharma Ltd. (Australian Stock Exchange (ASX); Symbol - CPH) whereby Creso will represent CanniMed in the European Union for the purpose of marketing all CanniMed® medical cannabis brands to governments, authorized importers and distributors, institutions,...
View More

CTT Pharmaceutical Holdings to License to CanniMed Ltd. Novel Cannabis Orally Dissolvable Thin Film (ODF) Wafer Drug Delivery Technology for North American Markets

August 23, 2016

Ottawa/SASKATOON, Aug. 11, 2016 -CanniMed Ltd. has entered into a letter of intent with CTT Pharmaceutical Holdings Inc. (OTCQB:CTTH) to license CTT’s Orally Dissolvable Thin Film (ODF) Wafer technology. This industry-first collaboration will enable CanniMed Ltd. to develop and commercialize this novel, smoke-free, drug delivery system in both Canada and...
View More
CanniMed Cares">

Get More From CanniMed Cares

July 14, 2016

The CanniMed Care Programs are about providing you with the extra care you deserve, the support you need, and the benefits you want. There’s no cost and complicated forms – once you become a CanniMed patient you’re in the program. Compassionate pricing for everyone* - Patient Direct Pricing gives you...
View More

CANNIMED OILS ARE IN STOCK

June 08, 2016

We were pleased to be one of the first Canadian LPs to fulfill all of Health Canada’s requirements granting us our expanded license under the Marihuana for Medical Purposes Regulations (MMPR) in order to produce and sell edible cannabis oils. Our three CanniMed® Oils are available and registered patients can...
View More